Broadcom CEO Hock Tan speaks alongside President Trump during an event to announce the company is moving its global headquarters to the United States. Photo: Evan Vucci / AP

U.S. chipmaker Qualcomm rejected rival Broadcom's $103 billion bid to purchase the company Monday, stating that Broadcom's proposal "dramatically undervalues" Qualcomm and comes with "significant regulatory uncertainty." Meanwhile, Broadcom said it is still "fully committed" to the deal, stating that they continue to believe their offer represents the most attractive, value-enhancing alternative available to Qualcomm stockholders.

Why it matters: If completed, the sale would have been the largest pure technology merger of all time. It also would have created the world's third-largest chipmaker, behind Intel and Samsung.

Background: Qualcomm CEO Steve Mollenkopf spent the last few days soliciting feedback from Qualcomm's shareholders, and determined that the offer does not price in the uncertainty associated with getting the deal approved by regulators.

What they're saying:

  • Qualcomm's presiding director, Tom Horton, said in a statement Monday that after conducting a comprehensive review of the bid, they concluded that Qualcomm's current plans provide "far superior value to Qualcomm shareholders than the proposed offer."
  • Broadcom said in a statement: "Many [of Qualcomm's stockholders] have expressed to us their desire that Qualcomm meet with us to discuss our proposal. It remains our strong preference to engage cooperatively with Qualcomm's Board of Directors and management team."

Last month, Broadcom announced that it would move its headquarters from Singapore to the U.S., in part due to the prospect for tax reform. Axios' Dan Primack points out the relocation was largely made to smooth the way not only for the Qualcomm deal, but also future M&A efforts.

Go deeper

Updated 6 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 10 p.m. EST: 32,135,220 — Total deaths: 981,660 — Total recoveries: 22,149,441Map.
  2. U.S.: Total confirmed cases as of 10 p.m EST: 6,975,980 — Total deaths: 202,738 — Total recoveries: 2,710,183 — Total tests: 98,481,026Map.
  3. Politics: House Democrats prepare new $2.4 trillion coronavirus relief package.
  4. Health: Cases are surging again in 22 states — New York will conduct its own review of coronavirus vaccine.
  5. Business: America is closing out its strongest quarter of economic growth.
  6. Technology: 2020 tech solutions may be sapping our resolve to beat the pandemic.
  7. Sports: Pac-12 will play this fall despite ongoing pandemic — Here's what college basketball will look like this season.
  8. Science: Global coronavirus vaccine initiative launches without U.S. or China — During COVID-19 shutdown, a common sparrow changed its song.
9 hours ago - Sports

Pac-12 will play football this fall, reversing course

A view of Levi's Stadium during the 2019 Pac-12 Championship football game. Photo: Alika Jenner/Getty Images

The Pac-12, which includes universities in Arizona, California, Colorado, Oregon, Utah and Washington state, will play football starting Nov. 6, reversing its earlier decision to postpone the season because of the coronavirus pandemic.

Why it matters: The conference's about-face follows a similar move by the Big Ten last week and comes as President Trump has publicly pressured sports to resume despite the ongoing pandemic. The Pac-12 will play a seven-game conference football season, according to ESPN.

Dave Lawler, author of World
10 hours ago - World

Global coronavirus vaccine initiative launches without U.S. or China

Data: Gavi, The Vaccine Alliance; Map: Naema Ahmed/Axios

A global initiative to ensure equitable distribution of coronavirus vaccines now includes most of the world — but not the U.S., China or Russia.

Why it matters: Assuming one or more vaccines ultimately gain approval, there will be a period of months or even years in which supply lags far behind global demand. The COVAX initiative is an attempt to ensure doses go where they're most needed, rather than simply to countries that can produce or buy them at scale.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!